Table 2: Characteristics of the 201 patients included in the study.

Recurrence T1
Progression
No
40 (20%)
Yes
161 (80%)
No
124 (62%)
Yes
77 (38%)

Gender
 Male34 (21%) 132 (79%)102 (62%)64 (38%)
 Female6 (17%)29 (83%)22 (61%)13 (39%)
WHO 99
 Grade 10000
 Grade 24 (12%) 26 (78%)20 (67%)10 (33%)
 Grade 336 (21%) 135 (79%) 104 (61%)67 (39%)
Tumour size
 ≤30 mm24 (26%) 71 (74%)60 (63%)35 (37%)
 >30 mm16 (15%) 90 (85%)64 (60%) 42 (40%)
Multiplicity
 Yes 32 (23%)110 (67%)86 (61%) 56 (39%)
 No7 (12%)51 (88%)38 (64%)21 (36%)
p53
 Normal4 (8%)45 (92%)26 (53%)23 (47%)
 Abnormal36 (24%)116 (76%)98 (64%)54 (36%)
p16
 Normal24 (23%)79 (77%)70 (68%)33 (72%)
 Abnormal16 (16%)82 (84%)54 (55%)44 (45%)
pRb
 Normal6 (18%)27 (82%)14 (42%)19 (58%)
 Abnormal34 (20%)134 (80%)110 (65%)58 (35%)
Cyclin D1
 Normal15 (24%)47 (76%)32 (53%)30 (47%)
 Abnormal29 (20%)114 (80%)96 (67%)47 (33%)
p21
 Normal7 (12%)42 (88%)32 (54%)17 (46%)
 Abnormal32 (21%)119 (79%)92 (61%)59 (39%)
MMP2
 Normal38 (21%)147 (79%)114 (63%)71 (37%)
 Abnormal4 (22%)14 (78%)12 (67%)6 (33%)
MMP9
 Normal35 (21%)128 (79%)104 (64%)59 (36%)
 Abnormal5 (13%)33 (87%)20 (53%)18 (47%)